After filing one lawsuit to try to block Novo Nordisk's $9 billion effort to trump the takeover, Pfizer has returned to the ...

But once a cancer has been detected, the ability to quickly specify exactly which treatment will work is set to have a transformative impact upon oncology, upon the wider world of medicine, and upon ...

The results of the ALLEGORY trial of Gazyva (obinutuzumab) suggest that the anti-CD20 antibody could have broad utility in ...

Tidmarsh, who was named as director of the Center for Drug Evaluation and Research (CDER) in July, told ABC in an interview ...

Pfizer has filed a lawsuit against Novo Nordisk and Metsera in an attempt to force through its takeover of the weight-loss drug developer and prevent Novo Nordisk from taking its rival bid forward.

Novartis' third-quarter results have exemplified the reason for its recent deal-making activity, as heart failure therapy Entresto finally succumbed to the entry of ...

MSD and Eisai's combination of Keytruda and Lenvima has become a driver of growth for both products, but their efforts to extend the regimen into liver cancer have hit a hurdle. The two partners said ...

CSL has said that with flu jab rates in the US down between 12% and 14% this year, it has decided to delay the planned spinout of its Seqirus vaccines business and cut its profit forecast for the ...

GSK has boosted its pipeline of antibody-drug conjugates for cancer, licensing a prostate cancer candidate from Syndivia in a deal that could be worth up to £268 million ($358 million). The object of ...

So it was that pharmaphorum sat down with Jan Kirsten, global head of the rare tumour business for SpringWorks Therapeutics – a healthcare company of Merck KGaA – to discuss mirdametinib’s application ...

Faced with soaring demand for leucovorin for use in children with autism, the American Academy of Paediatrics (AAP) has said ...

Final draft guidance on NHS use of the drug marks a "significant shift" from NICE's 2021 decision on the drug as a first-line ...